Literature DB >> 7847131

Prevention of delayed ischaemic deficits after aneurysmal subarachnoid haemorrhage by intrathecal bolus injection of tissue plasminogen activator (rTPA). A prospective study.

V Seifert1, D Stolke, M Zimmermann, A Feldges.   

Abstract

Among a series of 224 patients with aneurysmal subarachnoid haemorrhage (SAH) admitted over a period of three years, 52 patients were prospectively treated with intrathecal tissue plasminogen activator (rTPA). All of these patients were admitted and operated on within 72 h after SAH. SAH was confirmed by CT scan and the volume of blood accumulated in the basal cisterns was graded according to Fisher's scale. All patients had a SAH according to Fisher's grade III, as a prerequisite for inclusion into the study. In 21 patients additional intraventricular bleeding was detectable on CT scan. The diagnosis of a single intracerebral aneurysm as the bleeding source was established by pan-angiography, which also excluded additional cerebro-vascular malformations. The control group consisted of 68 patients, which were also treated within 72 h after SAH. Age and sex distribution as well as the clinical patterns were comparable to the rTPA group. In all patients the aneurysm was clipped using standard microsurgical techniques. After the aneurysm had been excluded from the parent vessel, 10 mg of rTPA, dissolved in 10 ml of its solution fluid, were slowly instilled into the basal cisterns in the treatment group. In patients with additional severe intraventricular bleeding, 5-10 mg of rTPA were injected into the ventricles via an intraventricular catheter at the end of the operation. Apart from the intrathecal application of the thrombolytic substance, the surgical protocol was identical in the patients of the control group. During the postoperative period, the patients in both groups were examined neurologically and by transcranial Doppler on a daily basis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7847131     DOI: 10.1007/bf01400664

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  27 in total

1.  Single intracisternal bolus of recombinant tissue plasminogen activator in patients with aneurysmal subarachnoid hemorrhage: preliminary assessment of efficacy and safety in an open clinical study.

Authors:  D Stolke; V Seifert
Journal:  Neurosurgery       Date:  1992-06       Impact factor: 4.654

2.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

3.  Assessment of outcome after severe brain damage.

Authors:  B Jennett; M Bond
Journal:  Lancet       Date:  1975-03-01       Impact factor: 79.321

4.  Experimental vasospasm in cultured arterial smooth-muscle cells. Part 1: Contractile and ultrastructural changes caused by oxyhemoglobin.

Authors:  S Fujii; K Fujitsu
Journal:  J Neurosurg       Date:  1988-07       Impact factor: 5.115

5.  The effect of timing of clot removal on chronic vasospasm in a primate model.

Authors:  Y Handa; B K Weir; M Nosko; R Mosewich; T Tsuji; M Grace
Journal:  J Neurosurg       Date:  1987-10       Impact factor: 5.115

6.  Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.

Authors:  J M Zabramski; R F Spetzler; K S Lee; S M Papadopoulos; E Bovill; R S Zimmerman; J B Bederson
Journal:  J Neurosurg       Date:  1991-08       Impact factor: 5.115

7.  Effect of clot removal at 24 hours on chronic vasospasm after SAH in the primate model.

Authors:  M Nosko; B K Weir; A Lunt; M Grace; P Allen; B Mielke
Journal:  J Neurosurg       Date:  1987-03       Impact factor: 5.115

8.  Chronic cerebral vasospasm: effect of volume and timing of hemorrhage in a canine model.

Authors:  J M Zabramski; R F Spetzler; C Bonstelle
Journal:  Neurosurgery       Date:  1986-01       Impact factor: 4.654

9.  Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage.

Authors:  J M Findlay; B K Weir; N F Kassell; L B Disney; M G Grace
Journal:  J Neurosurg       Date:  1991-08       Impact factor: 5.115

10.  Influence of blood volume on cerebrospinal fluid levels of arachidonic acid metabolites after subarachnoid hemorrhage: experimental study on the pathogenesis of cerebral vasospasm.

Authors:  V Seifert; D Stolke; U Kunz; K Resch
Journal:  Neurosurgery       Date:  1988-09       Impact factor: 4.654

View more
  6 in total

1.  The role of molecular biology in neurosurgery. Meeting of the Research Committee of the EANS in Hamburg, March 3-5, 1995.

Authors:  M Westphal; M Gerosa; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

2.  Thrombolysis for intraventricular hemorrhage after endovascular aneurysmal coiling.

Authors:  Bradley Hall; Dennis Parker; J Ricardo Carhuapoma
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Management of cerebral vasospasm.

Authors:  R Loch Macdonald
Journal:  Neurosurg Rev       Date:  2006-02-24       Impact factor: 3.042

Review 4.  A new perspective on cerebrospinal fluid dynamics after subarachnoid hemorrhage: From normal physiology to pathophysiological changes.

Authors:  Yuanjian Fang; Lei Huang; Xiaoyu Wang; Xiaoli Si; Cameron Lenahan; Hui Shi; Anwen Shao; Jiping Tang; Sheng Chen; Jianmin Zhang; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2021-11-22       Impact factor: 6.960

5.  Intrathecal Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage: Evidence From Randomized Controlled Trials and Cohort Studies.

Authors:  Xiaocheng Lu; Chengyuan Ji; Jiang Wu; Wanchun You; Wei Wang; Zhong Wang; Gang Chen
Journal:  Front Neurol       Date:  2019-08-19       Impact factor: 4.003

6.  Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future.

Authors:  Jennifer A Frontera
Journal:  Stroke Res Treat       Date:  2013-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.